Drug Trial Radar · NCT07704658
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Mar 4, 2026
Primary completion
Jul 30, 2027
Study completion Aug 30, 2027
Sponsor
- Lead sponsor
- Rigel PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors
Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Thyroid Cancer
- Solid Tumor Malignancies
- Advanced Malignancies
Interventions
PralsetinibDrug
Pralsetinib 400mg orally (PO) once daily (QD) from Day 4 to Day 10, with an option to continue up to Day 33
CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptiveDrug
Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO) once on Day 1 and once on Day 9.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf)Time frame: Up to 48 hours post-dose or as appropriate for each probe substrate
- Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)Time frame: Up to 48 hours after each probe drug administration
- Maximum Peak Plasma Concentration (Cmax)Time frame: Up to 48 hours after each probe drug administration
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitario HM Sanchinarro
Madrid, Spain · Recruiting
Hospital Universitario San Pedro
Logroño, La Rioja, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.